111 Diagnostic utility of molecular and imaging biomarkers 2 Table 5. Cytological BRAF mutation status in histopathologically confirmed malignancies BRAF mutation positive malignancies, ni BRAF mutation negative malignancies, ni reference PTC FVPTC FTC FTC-OV MTC mPTC other n.s. PTC FVPTC FTC FTC-OV MTC mPTC other n.s. Xing 2004 2 5 5 1 Sapio 2007 (1) 1 1 Sapio 2007 (2) 1 1 Kim 2008 13 3 2 3 Jo 2009 4 1 1 Marchetti 2009 3 Cantara 2010 2 5 Moses 2010 3 16 8 2 Adeniran 2011 (1) 16 11 Adeniran 2011 (2) 8 5 Kim 2011 30 2 4 Nikiforov 2011 5 2 10 67 9 Patel 2011 7 4 Pelizzo 2011 2 3 15 Yeo 2011 1 1 1 3 Canadas-Garre 2012 3 2 3 1 1 1 2 2 Kang 2012 1 5 Mancini 2012 2 7 Rossi 2012 14 23 5 1 1 Tonacchera 2012 1 4 7 2 Carr 2013 7 6 4 6 Jeong 2013 39 25 Kloos 2013 3 14 10 4 9 1 3 Koh 2013 5 12 Ohori 2013 7 6 89 4 5 2 1 Agretti 2014 1 8 2 3 Beaudenon 2014 11 5 1 Danilovic 2014 19 11 Eszlinger 2014 (1) 2 2 18 Eszlinger 2014 (2) 4 5 Hyeon 2014 87 37 Johnson 2014 1 1 3 6 6 Liu 2014 3 3 2 Nikiforov 2014 1 38 Park 2014 26 3 1 24 2 1 1 Poller 2014 1 Seo 2014 1 2 7 1 1 Borrelli 2015 3 3 8 Capelli 2015 4 12 2 2 Eszlinger 2015 5 5 2 6 21 5 1 Gill 2015 2 21 Giovanella 2015 3 2 5 5 1 Hwang 2015 37 6 3 35 2 Marino 2015 2 11 Le Mercier 2015 1 2 3 1 Nikiforov 2015 2 20 Park 2015 2 2 2 1 2 Rossi 2015 13 3 1 1 Beisa 2016 7 15 5 Kowalska 2016 2 1 1 4 Valderrabano 2016 1 13 2 1 1 1 TOTAL 308 37 0 1 0 3 0 68 202281143 31 7 9 11 194
RkJQdWJsaXNoZXIy MTk4NDMw